After going to Abington High School, Dr. Rosenwald began his medical schooling at PSU in 1973. He excelled a business and was particularly fascinated with economics and finance. Lindsay Rosenwald Graduated fro PSU in 1977 a part of Beta Gamma Sigma with a degree in finance. Regardless of his success in business, he now felt he had to go after his desire of becoming a physician.

In pursuit of his lifelong goal, Rosenwald joined Temple University’s University of Medicine. Following graduating from Temple University in 1983, he began an internship at Abington Hospital before beginning his own private practice. He worked as a doctor in his practice for two and a half years. Even though he cherished being a medical doctor, Rosenwald desired a profession where he could combine his two loves – medical science and business.

Rosenwald decide to depart private medical care in the mid eighties to take a job on Wall Street. The position he got was a Physician Analyst and amazingly fit exactly what he needed. Despite the misconception that doctors don’t make good investors, Dr Rosenwald excelled at this placement. He had a passion for growing investment finance open to the health care sector and that is primarily why he worked there. He received great admiration in his brand new placement, and though he missed his old private practice, he realized this is where he truly belonged. During this time, he also worked for DH Blair and Company, a private investment company, as the controlling director of corporate finance. Over time, he left D.H. Blair and Company to pay attention to a new venture and firm.

In 1991, Lindsay Rosenwald started Paramount Biotech. With time, he has expanded this company by establishing new companies and attaining control of other biotech companies. He has developed or financed over 40 companies – over 25 of that have been in the past 3 years. He can make these acquired businesses successful because he focuses on both improving the corporate structure of the organization, in addition to increasing the analysis portion. Now, Paramount Capital is comprised of a lot of companies. These companies include Paramount Biosciences, which produces and supports new biotechnology businesses, Paramount Corporate Improvement, which actively works to build the Paramount Corporation in addition to develop new medicines, and Paramount BioCapital, a broker-dealer that has raised over $950 billion in revenue since it started. The firms that Rosenwald controls have licensed or purchased over one hundred experimental stage medications.

One of the most notable achievements for Rosenwald is setting the record for the quickest approval of a new drug to market. In only thirty months, Arsenic Trioxide was created and authorized by the Food and drug administration for managing a deadly type of the leukemia disease. This medication has been in the marketplace globally for more than ten years and has saved and prolonged 1000s of lives.

Rosenwald has been groundbreaking with the businesses he has created. In one of the finest reverse mergers of all time, his company, Cougar Biotechnology, sold for over $1 billion to Johnson and Johnson, in spite of merely having a single medicine with phase two scientific data. He has also started the first publicly traded stem cell company, gene therapy company, and cancer vaccine company. As Rosenwald as the director, his businesses are creating probably the most valuable and groundbreaking drugs of the 21st century. He is also responsible for the very first successful anti-obesity drug created in the USA market in 30 years.

Many people credit the success of the biotech industry on a whole to Dr. Rosenwald. His visionary companies have altered many lives and made Dr. Rosenwald’s individual assets soar to the tune of $600 million.